Comparative Pharmacology
Head-to-head clinical analysis: NEOTRIZINE versus PROMETHACON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOTRIZINE versus PROMETHACON.
NEOTRIZINE vs PROMETHACON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neotrizine contains sulfadiazine, a competitive inhibitor of dihydropteroate synthase, blocking folic acid synthesis in susceptible bacteria.
Promethazine is a phenothiazine derivative with antihistaminic (H1 receptor antagonist), antiemetic, sedative, and anticholinergic properties. It inhibits central and peripheral H1 receptors, blocks dopamine D2 receptors in the chemoreceptor trigger zone, and has weak alpha-adrenergic blockade.
NEOTRIZINE (sulfamethoxazole/trimethoprim) 800 mg/160 mg orally every 12 hours for 5-14 days, depending on indication.
25-50 mg intramuscularly or intravenously every 4-6 hours as needed. Maximum intravenous rate: 25 mg/minute. Maximum daily dose: 150 mg.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in adults with normal renal function; in renal impairment, half-life may extend to 12-18 hours requiring dose adjustment.
Terminal elimination half-life: 4-6 hours in healthy adults; prolonged to 10-14 hours in hepatic impairment
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal elimination accounts for 20-30%, with the remainder as metabolites.
Renal (80%) as inactive metabolites, 20% fecal via bile
Category C
Category C
Antihistamine
Antihistamine